Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Liabilities and Shareholders Equity (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Liabilities and Shareholders Equity data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 84.05% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $3.4 billion, up 77.87%, while the annual FY2025 figure was $1.1 billion, 84.05% up from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per TGTX's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2025 and bottomed at $193.6 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $462.5 million, with a median of $390.4 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 438.74% in 2021, then tumbled 49.01% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $379.6 million in 2021, then crashed by 49.01% to $193.6 million in 2022, then soared by 70.27% to $329.6 million in 2023, then soared by 75.28% to $577.7 million in 2024, then surged by 84.05% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.1 billion in Q4 2025, $1.0 billion in Q3 2025, and $702.6 million in Q2 2025.